Viridian Therapeutics

Viridian Therapeutics is a biopharmaceutical company focused on developing new treatments for patients with rare diseases. The company leverages validated biology and target/pathway with the clinical development strategy in order to deliver improvements in access, quality of life and potentially efficacy. The lead program, VRDN-001, is an anti-IGF-1R antibody in development of thyroid eye disease.